SCHEMBL280130

SCHEMBL280130

Cc1ccc(C(=O)CSCc2ccncc2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.44
RAB9A P51151 6/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 4/20 0.42
HTT P42858 4/20 0.42
HPGD P15428 3/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
DAO P14920 1/20 0.42
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 3/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 2/20 0.39
ALOX12 P18054 1/20 0.39
POLB P06746 2/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
ALPG P10696 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280045 0.85 CHRNB2 (0.47) NPC1RAB9AL3MBTL1ALDH1A1HTT
SCHEMBL13060968 0.81 RAB9A (0.50) NPC1RAB9AL3MBTL1ALDH1A1HTT
SCHEMBL279929 0.75 POLB (0.47) NPC1RAB9AL3MBTL1ALDH1A1HTT
SCHEMBL280197 0.75 RAB9A (0.48) NPC1RAB9AL3MBTL1ALDH1A1HTT
SCHEMBL279743 0.74 NPC1 (0.41) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL10996122 0.74 CYP1A2 (0.53) ALDH1A1HTTMAPTSMN1; SMN2DAO
SCHEMBL279739 0.73 ALDH1A1 (0.47) NPC1RAB9AL3MBTL1ALDH1A1HTT
SCHEMBL279750 0.72 USP2 (0.43) NPC1RAB9AL3MBTL1ALDH1A1HTT
SCHEMBL8331326 0.72 HTT (0.56) ALDH1A1HTTSMN1; SMN2KMT2AHSD17B10
SCHEMBL10996270 0.72 ALDH1A1 (0.56) NPC1RAB9AL3MBTL1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL NPC1 3107/4885RAB9A 2458/4885L3MBTL1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.